154 related articles for article (PubMed ID: 30012192)
1. Community-based provision of direct-acting antiviral therapy for hepatitis C: study protocol and challenges of a randomized controlled trial.
Wade AJ; Doyle JS; Gane E; Stedman C; Draper B; Iser D; Roberts SK; Kemp W; Petrie D; Scott N; Higgs P; Agius PA; Roney J; Stothers L; Thompson AJ; Hellard ME
Trials; 2018 Jul; 19(1):383. PubMed ID: 30012192
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of Treatment for Hepatitis C in Primary Care, Compared to Hospital-based Care: A Randomized, Controlled Trial in People Who Inject Drugs.
Wade AJ; Doyle JS; Gane E; Stedman C; Draper B; Iser D; Roberts SK; Kemp W; Petrie D; Scott N; Higgs P; Agius PA; Roney J; Stothers L; Thompson AJ; Hellard ME
Clin Infect Dis; 2020 Apr; 70(9):1900-1906. PubMed ID: 31233117
[TBL] [Abstract][Full Text] [Related]
3. Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs.
Midgard H; Finbråten AK; Malme KB; Berg-Pedersen RM; Tanum L; Olsen IC; Bjørnestad R; Dalgard O
Trials; 2020 Jun; 21(1):524. PubMed ID: 32539853
[TBL] [Abstract][Full Text] [Related]
4. Financial incentives to motivate treatment for hepatitis C with direct acting antivirals among Australian adults (The Methodical evaluation and Optimisation of Targeted IncentiVes for Accessing Treatment of Early-stage hepatitis C: MOTIVATE-C): protocol for a dose-response randomised controlled study.
Fathima P; Jones M; D'Souza R; Totterdell J; Andric N; Abbott P; Norman R; Howard K; Cheng W; Pedrana A; Doyle JS; Davies J; Snelling T
Trials; 2024 Jun; 25(1):387. PubMed ID: 38886819
[TBL] [Abstract][Full Text] [Related]
5. Does a simplified algorithm and integrated HCV care model improve linkage to care, retention, and cure among people who inject drugs? A pragmatic quality improvement randomized controlled trial protocol.
Klaman SL; Godino JG; Northrup A; Lewis SV; Tam A; Carrillo C; Lewis R; Matthews E; Mendez B; Reyes L; Rojas S; Ramers C
BMC Infect Dis; 2024 Jan; 24(1):105. PubMed ID: 38238686
[TBL] [Abstract][Full Text] [Related]
6.
Byrne C; Radley A; Inglis SK; Beer LJZ; Palmer N; Pham MD; Healy B; Doyle JS; Donnan P; Dillon JF
BMJ Open; 2020 Aug; 10(8):e036501. PubMed ID: 32868356
[TBL] [Abstract][Full Text] [Related]
7. A systematic review and meta-analysis of community and primary-care-based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments.
Radley A; Robinson E; Aspinall EJ; Angus K; Tan L; Dillon JF
BMC Health Serv Res; 2019 Oct; 19(1):765. PubMed ID: 31660966
[TBL] [Abstract][Full Text] [Related]
8. Enablers and barriers for the provision of community-based HCV treatment: A case study of a real-world practice.
Pourmarzi D; Smirnov A; Hall L; Thompson H; FitzGerald G; Rahman T
J Viral Hepat; 2020 May; 27(5):484-496. PubMed ID: 31958355
[TBL] [Abstract][Full Text] [Related]
9. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
[TBL] [Abstract][Full Text] [Related]
10. Randomised controlled trial of active case management to link hepatitis C notifications to treatment in Tasmania, Australia: a study protocol.
Marukutira T; Moore KP; Hellard M; Richmond J; Turner K; Pedrana AE; Melody S; Johnston FH; Owen L; Van Den Boom W; Scott N; Thompson A; Iser D; Spelman T; Veitch M; Stoové MA; Doyle J
BMJ Open; 2022 Mar; 12(3):e056120. PubMed ID: 35338062
[TBL] [Abstract][Full Text] [Related]
11. The impact of universal access to direct-acting antiviral therapy on the hepatitis C cascade of care among individuals attending primary and community health services.
Traeger MW; Pedrana AE; van Santen DK; Doyle JS; Howell J; Thompson AJ; El-Hayek C; Asselin J; Polkinghorne V; Membrey D; Bramwell F; Carter A; Guy R; Stoové MA; Hellard ME;
PLoS One; 2020; 15(6):e0235445. PubMed ID: 32603349
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of a tertiary-based innovative approach to engage primary care providers in provision of hepatitis C treatment in community settings.
Pourmarzi D; Thompson H; Thomas JA; Hall L; Smirnov A; FitzGerald G; Rahman T
BMC Public Health; 2019 Oct; 19(1):1335. PubMed ID: 31640625
[TBL] [Abstract][Full Text] [Related]
13. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.
Scott N; Doyle JS; Wilson DP; Wade A; Howell J; Pedrana A; Thompson A; Hellard ME
Int J Drug Policy; 2017 Sep; 47():107-116. PubMed ID: 28797497
[TBL] [Abstract][Full Text] [Related]
14. Treatment access is only the first step to hepatitis C elimination: experience of universal anti-viral treatment access in Australia.
Doyle JS; Scott N; Sacks-Davis R; Pedrana AE; Thompson AJ; Hellard ME;
Aliment Pharmacol Ther; 2019 May; 49(9):1223-1229. PubMed ID: 30908706
[TBL] [Abstract][Full Text] [Related]
15. A population approach to disease management: hepatitis C direct-acting antiviral use in a large health care system.
Belperio PS; Backus LI; Ross D; Neuhauser MM; Mole LA
J Manag Care Spec Pharm; 2014 Jun; 20(6):533-40. PubMed ID: 24856591
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study.
Bajis S; Grebely J; Hajarizadeh B; Applegate T; Marshall AD; Ellen Harrod M; Byrne J; Bath N; Read P; Edwards M; Gorton C; Hayllar J; Cock V; Peterson S; Thomson C; Weltman M; Jefferies M; Wood W; Haber P; Ezard N; Martinello M; Maher L; Dore GJ;
J Viral Hepat; 2020 Mar; 27(3):281-293. PubMed ID: 31698545
[TBL] [Abstract][Full Text] [Related]
17. "Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs.
Goodyear T; Ti L; Carrieri P; Small W; Knight R
Int J Drug Policy; 2020 Jul; 81():102766. PubMed ID: 32416525
[TBL] [Abstract][Full Text] [Related]
18. Association of the Extension for Community Healthcare Outcomes Project With Use of Direct-Acting Antiviral Treatment Among US Adults With Hepatitis C.
Tran L; Feldman R; Riley T; Jung J
JAMA Netw Open; 2021 Jul; 4(7):e2115523. PubMed ID: 34213557
[TBL] [Abstract][Full Text] [Related]
19. A cluster randomized controlled trial of a MedicineInsight Educational Quality Improvement Programme to improve the diagnosis and treatment of chronic hepatitis C in general practice (the EQUIP-HEPC trial).
Chidwick K; Myton R; Rodgers A; Jun M; Dartnell J; Balcomb A; Dore G
J Viral Hepat; 2022 Feb; 29(2):135-146. PubMed ID: 34762764
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol).
Hickman M; Dillon JF; Elliott L; De Angelis D; Vickerman P; Foster G; Donnan P; Eriksen A; Flowers P; Goldberg D; Hollingworth W; Ijaz S; Liddell D; Mandal S; Martin N; Beer LJZ; Drysdale K; Fraser H; Glass R; Graham L; Gunson RN; Hamilton E; Harris H; Harris M; Harris R; Heinsbroek E; Hope V; Horwood J; Inglis SK; Innes H; Lane A; Meadows J; McAuley A; Metcalfe C; Migchelsen S; Murray A; Myring G; Palmateer NE; Presanis A; Radley A; Ramsay M; Samartsidis P; Simmons R; Sinka K; Vojt G; Ward Z; Whiteley D; Yeung A; Hutchinson SJ
BMJ Open; 2019 Sep; 9(9):e029538. PubMed ID: 31551376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
